Learn what deucravacitinib is, how its selective TYK2 allosteric inhibition works, and why it’s reshaping treatment for moderate‑to‑severe plaque psoriasis with biologic‑like efficacy and a differentiated safety profile.
Learn what deucravacitinib is, how its selective TYK2 allosteric inhibition works, and how it differs from traditional JAK inhibitors in autoimmune diseases like plaque psoriasis, psoriatic arthritis, SLE, and IBD.